Simplex Trading’s Cytek Biosciences CTKB Stock Holding History

Simplex Trading’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,500	Closed	-$24K	–	9439
2026 Q1	$24K	Hold	5,500	–	–	﹤0.01%	6616
2025 Q4	$27.8K	Buy	5,500 +4,700	+588%	+$21.8K	﹤0.01%	6176
2025 Q3	$2K	Hold	800	–	–	﹤0.01%	8620
2025 Q2	$2K	Buy	800 +300	+60%	+$1K	﹤0.01%	8104
2025 Q1	$2K	Buy	+500	New	+$2.59K	﹤0.01%	7954
2024 Q4	–	Sell	-1,000	Closed	-$5K	–	8668
2024 Q3	$5K	Hold	1,000	–	–	﹤0.01%	7591
2024 Q2	$5K	Buy	+1,000	New	+$6.01K	﹤0.01%	7844
2023 Q4	–	Sell	-500	Closed	-$2K	–	8930
2023 Q3	$2K	Hold	500	–	–	﹤0.01%	8059
2023 Q2	$4K	Buy	+500	New	+$4.49K	﹤0.01%	8013
2023 Q1	–	Sell	-200	Closed	-$2K	–	9176
2022 Q4	$2K	Buy	+200	New	+$2.69K	﹤0.01%	8544

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Simplex Trading's CTKB Position: Q2 2026 in Review

Simplex Trading sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 3,226 shares — an estimated $13.8K sold.

Simplex Trading first reported a position in CTKB in Q4 2023 and held it in 9 quarters. The position peaked at $14.1K in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Simplex Trading reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
Simplex Trading sold 3,226 Cytek Biosciences shares in Q2 2026, an estimated $13.8K.
Simplex Trading first reported a position in Cytek Biosciences in Q4 2023 and held it in 9 quarters.
Simplex Trading's Cytek Biosciences position peaked at $14.1K in Q1 2026.
155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.